KR970042518A - 트리아졸유도체,그의제조방법및이화합물을유효성분으로하는의약 - Google Patents
트리아졸유도체,그의제조방법및이화합물을유효성분으로하는의약 Download PDFInfo
- Publication number
- KR970042518A KR970042518A KR1019960067668A KR19960067668A KR970042518A KR 970042518 A KR970042518 A KR 970042518A KR 1019960067668 A KR1019960067668 A KR 1019960067668A KR 19960067668 A KR19960067668 A KR 19960067668A KR 970042518 A KR970042518 A KR 970042518A
- Authority
- KR
- South Korea
- Prior art keywords
- derivative
- salt
- formula
- triazole
- halogen atom
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/34—Compounds containing oxirane rings with hydrocarbon radicals, substituted by sulphur, selenium or tellurium atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epoxy Compounds (AREA)
Abstract
본 발명은 하기 화학식(1)의 트리아졸 유도체 또는 그 염, 그의 제조방법, 하기 화학식(2) 및 (3)의 제조 중간체 및 하기 화학식(1)의 화합물 또는 그염을 유효성분으로 함유하는 의약에 관한 것이다.
상기식에서, n 은 0,1 또는 2를 나타내고, X1은 수소원자 또는 불소원자를 나타내고, Y1 및 Y는 각각 독립적으로 수소원자, 할로겐원자 또는 트리플루오로메틸기를 나타낸다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (12)
- 하기 화학식(1)의 트리아졸 유도체 또는 그 염.상기식에서, Y1 및 Y는 같거나 상이하며, 각각 독립적으로 수소원자, 할로겐원자 또는 트리플루오로메틸기를 나타내고, n 은 0,1 또는 2를 나타낸다.
- 하기 화학식(2)의 2-(메틸티오)아세토페논 유도체.상기식에서, X1은 할로겐 또는 불소원자를 나타내고, Y1및 Y는 같거나 상이하며, 각각 독립적으로 수소원자, 할로겐원자 또는 트리플루오로메틸기를 나타낸다.
- 하기 화학식(3)의 화합물.상기식에서, Y1및 Y는 같거나 상이하며, 각각 독립적으로 수소원자, 할로겐원자 또는 트리플루오로메틸기를 나타낸다.
- 제 1 항에 따른 트리아졸 유도체(1) 또는 그 염의 제조방법으로서, 하기 화학식(2a)의 2-(메틸티오)아세토페논 유도체를 하기 화학식(2c)의 2,2-디플루오로-2-메틸티오아세토페논 유도체로 불소화시키고; 형성된 2,2-디르루오로-2-메틸티오세토페논 유도체를 에폭시메틸화제 및 1,2,4-트리아졸 또는 그 염과 반응시키고; 필요에 따라 산화시키는 것을 특징으로 하는 제조방법.상기식에서, Y1 및 Y는 같거나 상이하며, 각각 독립적으로 수소원자, 할로겐원자 또는 트리플루오로메틸기를 나타낸다.
- 제 1 항에 따른 트리아졸 유도체(1) 또는 그 염의 제조방법으로서, 하기 화학식(5)의 2-(할로게노)아세토페논 유도체에 메틸티오기를 도입시켜, 하기 화학식(2c)의 2,2-디플루오로-2-메틸티오아세토페논 유도체로 전환시키고; 형성된 유도체를 에폭시메틸화제 및 1,2,4-트리아졸 또는 그 염과 반응시키고; 필요에 따라 산화시키는 것을 특징으로 하는 제조방법.상기식에서, Y1 및 Y는 같거나 상이하며, 각각 독립적으로 수소원자, 할로겐원자 또는 트리플루오로메틸기를 나타내고, X는 할로겐원자를 나타낸다.
- 제 1 항에 따른 트리아졸 유도체 또는 그 염을 유효성분으로 하는 의약.
- 제 6 항에 있어서, 항진균제인 것을 특징으로 하는 의약.
- 제 1 항에 따른 트리아졸 유도체 또는 그 염 및 약제학적으로 허용가능한 담체를 포함하는 의약 조성물.
- 제 8 항에 있어서, 조성물이 항진균 조성물인 것을 특징으로 하는 의약 조성물.
- 의약으로서의 제 1 항에 따른 트리아졸 유도체 또는 그 염의 농도.
- 제 10 항에 있어서, 의약이 항진균제인 것을 특징으로 하는 용도.
- 제 1 항에 따른 트리아졸 유도체 또는 그 염의 유효량을 환자에게 투여하는 것을 특징으로 하는, 진균증의 치료방법.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP335251/1995 | 1995-12-22 | ||
JP33525195 | 1995-12-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR970042518A true KR970042518A (ko) | 1997-07-24 |
KR100262442B1 KR100262442B1 (ko) | 2000-08-01 |
Family
ID=18286437
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019960067668A KR100262442B1 (ko) | 1995-12-22 | 1996-12-19 | 트리아졸유도체,그의제조방법및이화합물을유호성분으로하는의약 |
Country Status (9)
Country | Link |
---|---|
US (2) | US5945438A (ko) |
EP (1) | EP0780380B1 (ko) |
KR (1) | KR100262442B1 (ko) |
CN (3) | CN1058005C (ko) |
CA (1) | CA2193182A1 (ko) |
DE (1) | DE69613328T2 (ko) |
ES (1) | ES2159676T3 (ko) |
HK (1) | HK1011020A1 (ko) |
TW (1) | TW383299B (ko) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW438784B (en) * | 1997-08-29 | 2001-06-07 | Ssp Co Ltd | Triazole derivative or salt thereof and pharmaceutical composition for treating mycosis containing the same |
JP3638438B2 (ja) * | 1997-12-26 | 2005-04-13 | エスエス製薬株式会社 | トリアゾール誘導体またはその塩、その製造方法及び当該化合物を有効成分とする医薬 |
EP0933368A1 (en) | 1998-02-02 | 1999-08-04 | SSP Co., Ltd. | Triazole derivative or salt thereof, preparation process thereof and pharmaceutical containing said compound as an effective ingredient (antimycotic) |
JP2000226368A (ja) * | 1999-02-04 | 2000-08-15 | Ss Pharmaceut Co Ltd | ジフルオロアセトフェノン誘導体の製造法 |
US6391903B1 (en) * | 1999-09-09 | 2002-05-21 | Sankyo Company, Limited | Triazole derivatives having antifungal activity |
KR20010050557A (ko) | 1999-09-29 | 2001-06-15 | 타이도 나오카타 | 아졸 유도체 또는 그의 염 |
HUP0004741A2 (hu) * | 2000-11-28 | 2002-12-28 | Sanofi-Synthelabo | Kémiai eljárás tiazolszármazékok előállítására és új intermedier |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3279417D1 (en) * | 1981-03-18 | 1989-03-09 | Ici Plc | Triazole compounds, a process for preparing them, their use as plant fungicides and fungicidal compositions containing them |
DK161382C (da) * | 1982-04-01 | 1991-12-09 | Pfizer | Fremgangsmaade til fremstilling af 1,2,4-triazol-forbindelser eller farmaceutisk acceptable syreadditionssalte deraf |
BG48681A3 (en) * | 1982-12-14 | 1991-04-15 | Ciba - Geigy Ag | Fungicide means |
GB8304282D0 (en) * | 1983-02-16 | 1983-03-23 | Pfizer Ltd | Antifungal agents |
EP0117100B1 (en) * | 1983-02-16 | 1986-12-10 | Pfizer Limited | Triazole antifungal agents |
JPH0383973A (ja) * | 1989-08-28 | 1991-04-09 | Sumitomo Pharmaceut Co Ltd | エポキシ体のスレオ選択的製造法 |
CA2031892C (en) * | 1989-12-25 | 2000-08-01 | Minoru Tokizawa | Triazole derivatives |
JP2530253B2 (ja) * | 1989-12-25 | 1996-09-04 | エスエス製薬株式会社 | トリアゾ―ル誘導体 |
JPH03284662A (ja) * | 1990-03-30 | 1991-12-16 | Asahi Glass Co Ltd | α―モノフルオロスルフィド及びその製造方法 |
JP3471831B2 (ja) * | 1991-12-09 | 2003-12-02 | 富山化学工業株式会社 | 新規なトリアゾール誘導体およびその塩 |
-
1996
- 1996-12-11 EP EP96119900A patent/EP0780380B1/en not_active Expired - Lifetime
- 1996-12-11 DE DE69613328T patent/DE69613328T2/de not_active Expired - Fee Related
- 1996-12-11 ES ES96119900T patent/ES2159676T3/es not_active Expired - Lifetime
- 1996-12-17 US US08/767,694 patent/US5945438A/en not_active Expired - Fee Related
- 1996-12-17 CA CA002193182A patent/CA2193182A1/en not_active Abandoned
- 1996-12-19 KR KR1019960067668A patent/KR100262442B1/ko not_active IP Right Cessation
- 1996-12-20 TW TW085115758A patent/TW383299B/zh not_active IP Right Cessation
- 1996-12-20 CN CN96123155A patent/CN1058005C/zh not_active Expired - Fee Related
-
1998
- 1998-11-13 HK HK98111991A patent/HK1011020A1/xx not_active IP Right Cessation
-
1999
- 1999-05-14 US US09/311,057 patent/US5986144A/en not_active Expired - Fee Related
-
2000
- 2000-03-01 CN CN00103657A patent/CN1286248A/zh active Pending
- 2000-03-01 CN CN00103658A patent/CN1289771A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
EP0780380A1 (en) | 1997-06-25 |
US5945438A (en) | 1999-08-31 |
US5986144A (en) | 1999-11-16 |
HK1011020A1 (en) | 1999-07-02 |
KR100262442B1 (ko) | 2000-08-01 |
TW383299B (en) | 2000-03-01 |
DE69613328D1 (de) | 2001-07-19 |
CN1058005C (zh) | 2000-11-01 |
CA2193182A1 (en) | 1997-06-23 |
EP0780380B1 (en) | 2001-06-13 |
CN1286248A (zh) | 2001-03-07 |
CN1159446A (zh) | 1997-09-17 |
ES2159676T3 (es) | 2001-10-16 |
DE69613328T2 (de) | 2001-09-20 |
CN1289771A (zh) | 2001-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3271269D1 (en) | Benzimidazole derivatives, process for the preparation thereof and pharmaceutical composition containing the same | |
CA2015475A1 (en) | Treating agent for osteoarthritis | |
EP0220523A3 (en) | Novel quinolinecarboxylic acid compounds, processes for preparing them, pharmaceutical composition and use | |
ES2051834T3 (es) | El uso de tetrahidrobenzeno(c,d)indol-6 carboxamidas para la preparacion de un medicamento para el tratamiento de la ansiedad. | |
IE870004L (en) | Optically pure compounds. | |
KR970042518A (ko) | 트리아졸유도체,그의제조방법및이화합물을유효성분으로하는의약 | |
ZA863382B (en) | Quinolylglycinamide derivatives,the process for preparation thereof and their therapeutic application as psychotropic drugs | |
KR910000647A (ko) | 나프틸아미노-및 나프틸옥시- 피리딘아민 및 관련된 화합물, 이의 제조방법 및 이의 피부소염제로서의 용도 | |
HUT61968A (en) | Process for producing 2-hydroxy-2-phenylethyl amino compounds and pharmaceutical compositions comprising such active ingredient | |
DE69120699D1 (de) | N-Monosubstituierte Cyclopentenylamine, ein Verfahren zu ihrer Herstellung, und ihre Verwendung als Medikament | |
KR950031075A (ko) | 새로운 3-페닐설포닐-3,7-디아자바이사이클로[3, 3, 1]노난-화합물을 함유하는 약제 | |
NO913023D0 (no) | Nye bicykliske aminosubstituerte forbindelsr. | |
EP1400512A1 (en) | Crystalline organic acid salt of amlodipine | |
IT1115155B (it) | Preparato farmaceutico contenente un derivato di acido orto-amminobenzoico come ingrediente attivo | |
KR930000523A (ko) | 신규한 세펨 화합물 | |
ATE50248T1 (de) | Ein imidazolidintrion-derivat oder ein seiner pharmazeutisch akzeptierbaren salze enthaltende pharmazeutische zusammenstellung. | |
KR870003098A (ko) | 치환된 3-(4-페닐-1-피페라지닐)알킬퀴나졸린-2,4-(1h,3h)디온의 제조방법 | |
AU579295B2 (en) | New thiazole derivatives, a process for the preparation thereof and pharmaceutical compositions containing them | |
KR920016426A (ko) | 9-아미노테트라하이드로아크리딘 화합물, 이의 제조방법 및 약제로서의 이의 용도 | |
RU2000125095A (ru) | Фунгицидная композиция, включающая бензоилфенилмочевину | |
KR880006198A (ko) | 2,6-디아미노-3- 할로벤질피리딘, 이의 제조방법 및 이의 약제학적 용도 | |
DE69719473T2 (de) | Optisch aktive (R)-(E)-(4-substituierte Phenyl-1,3-Dithiolan-2-Ylidene)-1-Imidazolylacetonitrilederivative und ihre Verwendung als Fungizide | |
EP0189080A3 (en) | (1,2,4-oxadiazol-3-yl)-arylmethanones, a process for their preparation and their use as medicaments | |
EP0393538A3 (en) | Thiazetoquinoline-3-carboxylic acid derivative, method for preparation thereof, and a pharmaceutical composition comprising the same | |
ATE11530T1 (de) | P-chlorophenoxyessigsaeure-derivat, verfahren zu dessen herstellung und pharmazeutische zusammenstellung. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20030422 Year of fee payment: 4 |
|
LAPS | Lapse due to unpaid annual fee |